AI Article Synopsis
- The study investigates indolent IDH-wildtype diffuse gliomas (iDGwt) that are typically treated as glioblastoma but may have less aggressive clinical behavior.
- Researchers analyzed adult patients with IDHwt gliomas from 2011 to 2020, defining clinical indolence based on small lesions and stable conditions before surgery, while comparing genetic data to a reference cohort.
- The findings revealed that only 5% of surveyed cases were classified as iDGwt, which showed fewer genetic alterations associated with aggressive gliomas and a significantly longer median survival rate of 37.5 months compared to the typical glioblastoma survival of 13.9 months.
Article Abstract
Purpose: IDH-wildtype (IDHwt) diffuse gliomas are treated as glioblastoma, however, some of these may show less aggressive clinical courses. The authors investigated the clinical, histopathological, and molecular characteristics of such IDHwt indolent diffuse gliomas (iDGwt), which have not been well documented in the literature.
Methods: Adult patients with IDHwt gliomas admitted between 2011 and 2020 were surveyed. In this particular study, the clinical indolence was defined mainly as having a small enhancing lesion and a stable period for more than 1 month before surgery. The current WHO diagnostic criteria were adapted for the diagnoses. Gene mutations and copy number changes in 43 representative glioma-associated genes, MGMT promoter methylation status, and survival data were compared with those of The Cancer Genome Atlas reference cohort.
Results: Nine out of 180 surveyed cases (5.0%) fulfilled the present criteria of the iDGwt. Considering the representative regulatory pathways, 8 (88.9%), 4 (44.4%), and 1 (11.1%) case had genetic alterations in the PI3K/MAPK, TP53, and RB pathways, respectively. The frequency of the RB pathway alteration was significantly lower than that in the reference cohort (281 of 362 cases: 77.6%). Two cases (22.2%) showing EGFR amplification met the diagnostic criteria for glioblastoma, and the frequency was significantly lower than that in the reference cohort (412 of 426 cases: 96.7%). The overall survival (median: 37.5 months) in the present series was significantly longer than that in the reference cohort (n = 426, median: 13.9 months).
Conclusions: iDGwt lacked the molecular features of glioblastoma except for the PI3K/MAPK pathway alteration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11060-022-04074-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!